Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.

Abstract:

BACKGROUND:Adjuvants like AS01B increase the immunogenicity of vaccines and generally cause increased transient reactogenicity compared with Alum. A phase II randomized trial was conducted to characterize the response to AS01B and Alum adjuvanted vaccines. A post-hoc analysis was performed to examine the associations between reactogenicity and innate immune parameters. METHODS:The trial involved 60 hepatitis B-naïve adults aged 18-45 years randomized 1:1 to receive either two doses of HBsAg-AS01B on Day (D)0 and D30, or three doses of HBsAg-Alum on D0, D30, D180. Prior to vaccination, all subjects received placebo injection in order to differentiate the impact of injection process and the vaccination. Main outcomes included reactogenicity symptoms, vital signs, blood cytokines, biochemical and hematological parameters after vaccination. Associations were explored using linear regression. FINDINGS:The vaccine with AS01B induced higher HBsAg-specific antibody levels than Alum. Local and systemic symptoms were more frequent in individuals who received HBsAg AS01B/Alum vaccine or placebo, but were mild and short-lived. Blood levels of C-reactive protein (CRP), bilirubin, leukocyte, monocyte and neutrophil counts increased rapidly and transiently after AS01B but not after Alum or placebo. Lymphocyte counts decreased in the AS01B group and lactate dehydrogenase levels decreased after Alum. Modelling revealed associations between systemic symptoms and increased levels of CRP and IL-6 after the first HBsAg-AS01B or HBsAg-Alum immunization. Following the second vaccine dose, CRP, IL-6, IP-10, IFN-γ, MIP-1β and MCP-2 were identified as key parameters associated with systemic symptoms. These observations were confirmed using an independent data set extracted from a previous study of the immune response to HBsAg-adjuvanted vaccines (NCT00805389). CONCLUSIONS:IL-6 and IFN-γ signals were associated with systemic reactogenicity following administration of AS01B-adjuvanted vaccine. These signals were similar to those previously associated with antibody and T-cell responses induced by HBsAg-adjuvanted vaccines, suggesting that similar innate immune signals may underlie adjuvant reactogenicity and immunogenicity. TRIAL REGISTRATION:www.clinicaltrials.gov NCT01777295.

journal_name

Vaccine

journal_title

Vaccine

authors

Burny W,Marchant A,Hervé C,Callegaro A,Caubet M,Fissette L,Gheyle L,Legrand C,Ndour C,Tavares Da Silva F,van der Most R,Willems F,Didierlaurent AM,Yarzabal J,ECR-008 study group.

doi

10.1016/j.vaccine.2019.02.015

subject

Has Abstract

pub_date

2019-03-28 00:00:00

pages

2004-2015

issue

14

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(19)30209-9

journal_volume

37

pub_type

杂志文章,随机对照试验

相关文献

VACCINE文献大全
  • Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.

    abstract::Defective interfering (DI) virus RNAs result from major deletions in full-length viral RNAs that occur spontaneously during de novo RNA synthesis. These RNAs are packaged into virions that are by definition non-infectious, and are delivered to cells normally targeted by the virion. DI RNAs can only replicate with the ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.03.004

    authors: Mann A,Marriott AC,Balasingam S,Lambkin R,Oxford JS,Dimmock NJ

    更新日期:2006-05-15 00:00:00

  • Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches.

    abstract::Influenza viruses exhibit a fascinating level of antigenic heterogeneity that facilitates re-infection in the human population. The human antibody repertoire also manifests endless capability for variation in the genes that specify the portion of antibody molecules interacting with epitopes. A recent explosion of tech...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.124

    authors: Crowe JE Jr

    更新日期:2009-12-30 00:00:00

  • The use of sequence analysis of a feline calicivirus (FCV) hypervariable region in the epidemiological investigation of FCV related disease and vaccine failures.

    abstract::A reverse transcriptase polymerase chain reaction (PCR) was used to amplify a 235 bp hypervariable region of the feline calicivirus (FCV) genome which encodes part of the capsid protein. Sequence from this region was used to compare viruses used in three attenuated vaccines to viruses isolated from vaccinated cats wit...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00059-5

    authors: Radford AD,Bennett M,McArdle F,Dawson S,Turner PC,Glenn MA,Gaskell RM

    更新日期:1997-08-01 00:00:00

  • Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study.

    abstract::We sought to determine the vaccine effectiveness (VE) of Lanzhou lamb rotavirus (LLR) vaccine against rotavirus gastroenteritis in children <5 requiring hospitalization. Children hospitalized 2002-2004 with rotavirus gastroenteritis were matched by gender, age and community to 838 controls. VE was calculated for one o...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.10.036

    authors: Fu C,Wang M,Liang J,He T,Wang D,Xu J

    更新日期:2007-12-17 00:00:00

  • Seroprevalence of mumps in an epidemic period in Medellín, Colombia.

    abstract:OBJECTIVE:We related seroprevalence and outbreaks data in order to identify factors that could explain the occurrence of outbreaks despite high vaccination coverage in Medellín Colombia. METHODS:Samples from a population seroprevalence data obtained in 2009 in a random survey were analyzed. IgG levels were determined ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.08.088

    authors: Santacruz-Sanmartín E,Hincapié-Palacio D,Ospina MC,Perez-Toro O,Bernal-Restrepo LM,Buitrago-Giraldo S,Lenis-Ballesteros V,Díaz FJ

    更新日期:2015-10-13 00:00:00

  • Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA.

    abstract::Pneumococcal type 1 pilus proteins have been proposed as potential vaccine candidates. Following conjugate pneumococcal vaccination, the prevalence of the pneumococcal type 1 pilus declined dramatically, a decline associated with the elimination of vaccine-type (VT) strains. Here we show that between 2004 and 2007, th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.04.042

    authors: Regev-Yochay G,Hanage WP,Trzcinski K,Rifas-Shiman SL,Lee G,Bessolo A,Huang SS,Pelton SI,McAdam AJ,Finkelstein JA,Lipsitch M,Malley R

    更新日期:2010-07-05 00:00:00

  • A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy.

    abstract::Although concerns about safety of influenza vaccination during pregnancy have been raised in the past, vaccination of pregnant women was recommended in many countries during the 2009 A/H1N1 pandemic influenza. A retrospective cohort study was conducted to evaluate the risk of adverse maternal, fetal and neonatal outco...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.03.041

    authors: Fabiani M,Bella A,Rota MC,Clagnan E,Gallo T,D'Amato M,Pezzotti P,Ferrara L,Demicheli V,Martinelli D,Prato R,Rizzo C

    更新日期:2015-05-05 00:00:00

  • Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.

    abstract::African horse sickness is a lethal viral disease of equids transmitted by biting midges of the Genus Culicoides. The disease is endemic to sub-Saharan Africa but outbreaks of high mortality and economic impact have occurred in the past in non-endemic regions of Africa, Asia and Southern Europe. Vaccination is critical...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.04.005

    authors: Manning NM,Bachanek-Bankowska K,Mertens PPC,Castillo-Olivares J

    更新日期:2017-10-20 00:00:00

  • DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus.

    abstract::Dengue is one of the most important mosquito-borne viral disease causing dengue fever and/or dengue shock syndrome/haemorrhagic fever. In some reports, the non-structural protein 1 (NS1) has been identified as a promising antigen for the development of vaccines against dengue virus (DENV). Apparently, it can elicit a ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.022

    authors: Costa SM,Freire MS,Alves AM

    更新日期:2006-05-22 00:00:00

  • Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

    abstract::Plasmid DNA is a promising vaccine platform that has been shown to be safe and able to be administered repeatedly without vector interference. Enhancing the potency of DNA vaccination through co-delivery of molecular adjuvants is one strategy currently under investigation. Here we describe the use of the novel chemoki...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.095

    authors: Kraynyak KA,Kutzler MA,Cisper NJ,Khan AS,Draghia-Akli R,Sardesal NY,Lewis MG,Yan J,Weiner DB

    更新日期:2010-02-23 00:00:00

  • Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimurium generate effective anti-tumor immunity.

    abstract::Gram-negative bacterial outer membrane proteins (Omps) have an important role in pathogenesis and signal reception. We previously reported that Acinetobacter OmpA (AbOmpA) induced maturation of bone marrow-derived dendritic cells (BMDCs) and that AbOmpA-primed DCs produced IL-12 which generated Th1 CD4(+) T-cells. We ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.01.036

    authors: Jang MJ,Kim JE,Chung YH,Lee WB,Shin YK,Lee JS,Kim D,Park YM

    更新日期:2011-03-16 00:00:00

  • A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination.

    abstract::Universal infant vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) has nearly eliminated PCV7-serotype invasive pneumococcal disease (IPD) in young U.S. children, but has been accompanied by increases in the incidence of serotype 19A IPD. Because antibiotic-non-susceptible 19A has increased more than...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.03.030

    authors: Van Effelterre T,Moore MR,Fierens F,Whitney CG,White L,Pelton SI,Hausdorff WP

    更新日期:2010-05-07 00:00:00

  • National surveillance of invasive pneumococcal diseases in Taiwan, 2008-2012: differential temporal emergence of serotype 19A.

    abstract:INTRODUCTION:Serotype replacement after the introduction of seven-valent pneumococcal conjugate vaccine (PCV7) and the future availability of multivalent PCVs prompted the listing of invasive pneumococcal disease (IPD) as a notifiable disease in Taiwan in October 2007. Here, we report the national surveillance results....

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.04.061

    authors: Chiang CS,Chen YY,Jiang SF,Liu DP,Kao PH,Teng HJ,Kuo TL,Yao SM,Tseng LR,Wang YL,Wu HS,Chang FY,Lin TY

    更新日期:2014-06-05 00:00:00

  • Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.

    abstract::Persistence of antibodies following a single dose of Tdap vaccine (tetanus, diphtheria, and five-component acellular pertussis vaccine for use in individuals past childhood) was evaluated in a follow-up of adolescents (N=324) and adults (N=644) who had received Tdap in earlier clinical trials. Outcome measures were se...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.09.031

    authors: Barreto L,Guasparini R,Meekison W,Noya F,Young L,Mills E

    更新日期:2007-11-23 00:00:00

  • Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge.

    abstract::To test several vaccines for Chlamydia trachomatis we vaccinated BALB/c and C3H/HeN female mice with a purified preparation of the native mouse pneumonitis (MoPn) major outer membrane protein (MOMP). The MOMP was formulated with anyone of three different adjuvants MF59, LT-K63 or LT-R72. As a negative control the anim...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.074

    authors: Pal S,Peterson EM,Rappuoli R,Ratti G,de la Maza LM

    更新日期:2006-02-06 00:00:00

  • Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

    abstract::Although a highly effective vaccine against smallpox, vaccinia virus (VV) is not without adverse events, some of which can be life-threatening, particularly in immunocompromised individuals. We have recently demonstrated that the immunogenicity and protective efficacy of Dryvax(®) in immunocompetent mice is preserved ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.10.039

    authors: Berhanu A,King DS,Mosier S,Jordan R,Jones KF,Hruby DE,Grosenbach DW

    更新日期:2010-12-16 00:00:00

  • Modeling cervical cancer prevention in developed countries.

    abstract::Cytology-based screening has reduced cervical cancer mortality in countries able to implement, sustain and financially support organized programs that achieve broad coverage. These ongoing secondary prevention efforts considerably complicate the question of whether vaccination against human papillomavirus (HPV) types ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2008.06.009

    authors: Kim JJ,Brisson M,Edmunds WJ,Goldie SJ

    更新日期:2008-08-19 00:00:00

  • Factors affecting Salmonella-based combination immunotherapy for prevention of type 1 diabetes in non-obese diabetic mice.

    abstract::We previously reported the development of an oral vaccine for diabetes based on live attenuated Salmonella-expressing preproinsulin (PPI) as the autoantigen. When combined with host cell-expressed TGFβ, the vaccine prevented the onset of diabetes in non-obese diabetic (NOD) mice. Herein, we investigated factors that c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.10.101

    authors: Husseiny MI,Du W,Mbongue J,Lenz A,Rawson J,Kandeel F,Ferreri K

    更新日期:2018-12-18 00:00:00

  • Cytokine production patterns and antibody response to measles vaccine.

    abstract::Cytokines play an important role in the immune response to live measles virus immunization. To gain further insight into the cytokine production profile in response to measles vaccination, we studied interferon-gamma (IFN-gamma), tumor necrosis factor (TNF-alpha), soluble IL-2 receptor (sIL-2R), interleukin-2 (IL-2), ...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0264-410x(03)00272-x

    authors: Ovsyannikova IG,Reid KC,Jacobson RM,Oberg AL,Klee GG,Poland GA

    更新日期:2003-09-08 00:00:00

  • Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.

    abstract::A novel avian-origin influenza A H7N9 virus emerged in China in 2013 and continues to cause sporadic human infections with mortality rates approaching 35%. Currently there are no approved human vaccines for H7N9 virus. Recombinant approaches including hemagglutinin (HA) and virus-like particles (VLPs) have resulted in...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.07.026

    authors: Pushko P,Pujanauski LM,Sun X,Pearce M,Hidajat R,Kort T,Schwartzman LM,Tretyakova I,Chunqing L,Taubenberger JK,Tumpey TM

    更新日期:2015-09-11 00:00:00

  • Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review.

    abstract:BACKGROUND:Currently, one lifetime booster of a 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for those at highest risk of invasive pneumococcal disease (IPD) 3-5 years after initial vaccination. Due to a lack of evidence on multiple revaccinations, recommendations on repeat revaccination do not ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.01.060

    authors: Caya CA,Boikos C,Desai S,Quach C

    更新日期:2015-03-10 00:00:00

  • Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.

    abstract::As a recently launched novel vaccine used as one of the vaccines for the final eradication of polios worldwide, complete data on the consistency and immunogenicity characteristics of the inactivated poliomyelitis vaccine made from the Sabin strain (sIPV) and its safety in large-scale populations are required to suppor...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2021.01.027

    authors: Jiang R,Liu X,Sun X,Wang J,Huang Z,Li C,Li Z,Zhou J,Pu Y,Ying Z,Yin Q,Zhao Z,Zhang L,Lei J,Bao W,Jiang Y,Dou Y,Li J,Yang H,Cai W,Deng Y,Che Y,Shi L,Sun M

    更新日期:2021-01-21 00:00:00

  • Persistence of long-term immunity to hepatitis B among adolescents immunized at birth.

    abstract::The long-term duration of recombinant hepatitis B vaccine-induced immunity among persons vaccinated starting at birth is still not well understood. Waning of vaccine-induced immunity could leave young adults at risk of hepatitis B virus infection due to behavioral or occupational exposures. We followed a cohort of chi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.106

    authors: Chaves SS,Fischer G,Groeger J,Patel PR,Thompson ND,Teshale EH,Stevenson K,Yano VM,Armstrong GL,Samandari T,Kamili S,Drobeniuc J,Hu DJ

    更新日期:2012-02-21 00:00:00

  • Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002.

    abstract:BACKGROUND:As part of the regulatory requirements, serological evaluation of trivalent inactivated influenza vaccines must be performed before annual re-licensure in the European Union. These studies are typically set up as uncontrolled, open label trials including 2 groups of at least 50 healthy adults and healthy eld...

    journal_title:Vaccine

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.vaccine.2009.09.138

    authors: Voordouw AC,Beyer WE,Smith DJ,Sturkenboom MC,Stricker BH

    更新日期:2009-12-11 00:00:00

  • Perspectives on the control of hepatitis A by vaccination.

    abstract::The availability of an inactivated hepatitis A virus (HAV) vaccine, and the development of live attenuated virus vaccines against hepatitis represent great advances in the effort to control an important cause of viral hepatitis. There are a number of ways hepatitis A vaccines could be used, depending on the epidemiolo...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/0264-410x(92)90555-x

    authors: Kane MA

    更新日期:1992-01-01 00:00:00

  • Genetic immunization with GPI-anchored anthrax protective antigen raises combined CD1d- and MHC II-restricted antibody responses by natural killer T cell-mediated help.

    abstract::Studies have demonstrated that lipid rafts ultimately regulate the endocytosis of anthrax toxin via clathrin dependent pathway. Interestingly, GPI-anchored protein rich rafts have also been shown to be transported down to the endocytic pathway to reducing late endosomes. Taking advantage of this parallelism, we tried ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.042

    authors: Midha S,Bhatnagar R

    更新日期:2009-03-10 00:00:00

  • Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density.

    abstract::Widespread use of Pneumococcal Conjugate Vaccines (PCV) has reduced vaccine-type nasopharyngeal colonisation and invasive pneumococcal disease. In a double-blind, randomised controlled trial using the Experimental Human Pneumococcal Challenge (EHPC) model, PCV-13 (Prevenar-13) conferred 78% protection against colonisa...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2019.05.080

    authors: German EL,Solórzano C,Sunny S,Dunne F,Gritzfeld JF,Mitsi E,Nikolaou E,Hyder-Wright AD,Collins AM,Gordon SB,Ferreira DM

    更新日期:2019-07-09 00:00:00

  • Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.

    abstract::Bordetella parapertussis, a close related species of B. pertussis, can also cause the disease named pertussis or whooping cough. The number of cases caused by this related pathogen has risen sustained in the last years. The widely used cellular (wP) or acellular (aP) pertussis vaccines have little or no efficacy again...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.08.059

    authors: Bottero D,Gaillard ME,Errea A,Moreno G,Zurita E,Pianciola L,Rumbo M,Hozbor D

    更新日期:2013-10-25 00:00:00

  • A randomized, placebo-controlled study of oral cimetidine as an immunopotentiator of parenteral immunization with a group B meningococcal vaccine.

    abstract::Cimetidine (CIM) is an H2-receptor antagonist with a long history of clinical use in peptic ulcer disease. In addition to its inhibitory effect upon gastric acid secretion, CIM can also block histamine-mediated immunosuppression by inhibiting H2 receptors on suppressor T cells. CIM results in immunoaugmentation of bot...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(96)00311-8

    authors: Drabick JJ,Tang DB,Moran EE,Trofa AF,Foster JS,Zollinger WD

    更新日期:1997-07-01 00:00:00

  • CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.

    abstract::Understanding the requirements for protection against pneumococcal carriage and pneumonia will greatly benefit efforts in controlling these diseases. Several antigens, in addition to the polysaccharide capsule, have been implicated in both the virulence and protective immunity against Streptococcus pneumoniae; one of ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.020

    authors: Singh R,Singh S,Briles DE,Taub DD,Hollingshead SK,Lillard JW Jr

    更新日期:2012-02-01 00:00:00